Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 10, 2017

View Archived Issues

Lundbeck recaps progress of fourth quarter 2016

ASLAN Pharmaceuticals presents phase II results for varlitinib

Treatment with MD-1003 shows efficacy and safety in patients with progressive multiple sclerosis

Promising inhibitors of STOML3 oligomerization in treating tactile-driven pain following neuropathy

Kagoshima University identifies novel anti-hepatitis B virus agents

Neurocrine and Bial sign licensing agreement for opicapone in U.S. and Canada

SC-83288, a clinical development candidate with novel mode of action for the treatment of malaria

Update on phase III trials of NC-6004 for the treatment of pancreatic cancer

CEVEC Pharmaceuticals signs agreement with NewLink Genetics for use of its cell lines

Phase I results show UE-2343 is brain penetrant and well tolerated

Armetheon agrees with FDA on phase III study for oral anticoagulant

Tracon reports phase II topline results for TRC-105 in recurrent glioblastoma

Marathon Pharmaceuticals' Emflaza approved by FDA for DMD

Viking Therapeutics reports results on VK-2809 in model of GSD Ia

MRC, South African MRC and GSK partner to tackle noncommunicable diseases in Africa

MediWound reports favorable results from phase II study of NexoBrid

Ovid Therapeutics enters Angelman syndrome biomarker collaboration, begins phase II study

Tessa Therapeutics and A*STAR's IMCB collaborate on immuno-oncology lab

Copanlisib named FDA orphan drug for splenic, nodal and extranodal marginal zone lymphoma

FDA names laquinimod sodium an orphan drug for Huntington's disease

Generex continues process to acquire controlling equity interest in Emmaus Life Sciences

U.S. orphan drug designation granted to IMG-7289 for acute myeloid leukemia

Blood NF-L, a promising biomarker for differential diagnosis of parkinsonian disorder

Systems Oncology signs license agreement with University of Wisconsin-Milwaukee

Prevacus plans phase I studies of PRV-002 to treat concussion

Boehringer Ingelheim starts phase II trial to treat advanced squamous cell carcinoma of the lung

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...